Found: 8
Select item for more details and to access through your institution.
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5027, doi. 10.3390/cancers15205027
- By:
- Publication type:
- Article
Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 2, p. 197, doi. 10.1111/ejh.13192
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00834-6
- By:
- Publication type:
- Article
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 11, p. 1704, doi. 10.1002/cncr.34722
- By:
- Publication type:
- Article
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2657, doi. 10.1002/cncr.33541
- By:
- Publication type:
- Article
Severe peripheral arterial disease during nilotinib therapy.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Severe Peripheral Arterial Disease During Nilotinib Therapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 17, p. 1347, doi. 10.1093/jnci/djr292
- By:
- Publication type:
- Article